New EASD-ADA consensus guidelines on managing hyperglycaemia in type 2 diabetes launched at EASD meeting

October 5, 2018, Diabetologia

Following a review of the latest evidence —including a range of recent trials of drug and lifestyle interventions—the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) have produced an updated consensus statement on how to manage hyperglycaemia (high blood sugar) in patients with type 2 diabetes. The consensus paper is being co-published in Diabetologia, the journal of EASD, and Diabetes Care, the journal of the ADA, during the annual meeting of EASD in Berlin, Germany.

The new recommendations from the expert panel from both societies, which update their previous 2015 guidance, include:

  • Providers and healthcare systems should prioritise the delivery of patient-centred care
  • Facilitating adherence should be specifically-considered when selecting glucose-lowering medications. (Ultimately, patient preference is a major factor driving the choice of medication. Even in cases where a patient's clinical characteristics suggest the use of a particular medication based on the available evidence from clinical trials, patient preferences regarding route of administration, injection devices, side effects or cost may prevent their use by some individuals)
  • All should have ongoing access to self-management education and support
  • Medical nutrition therapy (healthy eating advice and strategies) should be offered to all patients
  • All overweight and obese patients with diabetes should be advised of the health benefits of weight loss and encouraged to engage in a programme of intensive lifestyle management, which may include food substitution
  • Increasing physical activity improves glycaemic control and should be encouraged in all people with type 2 diabetes.
  • Metabolic surgery is a recommended treatment option for adults with type 2 diabetes and (1) a BMI of 40 or over (or 37.5 or over in people of Asian ancestry) or (2) a BMI of 35.0 to 39.9 (32.5-37.4 kg/m2 in people of Asian ancestry) who do not achieve durable weight loss and improvement in comorbidities with reasonable non-surgical methods.
  • Metformin continues to be the first-line recommended therapy for almost all patients with type 2 diabetes
  • The selection of medication added to metformin is based on patient preference and clinical characteristics, including presence of cardiovascular disease, heart failure and kidney disease. The risk for specific adverse medication effects, particularly hypoglycaemia and weight gain; as well as safety, tolerability, and cost, are also important considerations.
  • Regarding medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. Individual agents within these drug classes have been shown to have cardiovascular benefits.
  • For patients with chronic (CKD) or clinical and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit should be considered
  • GLP-1 receptor agonists are generally recommended as the first injectable medication, except in settings where type 1 diabetes is suspected
  • Intensification of treatment beyond dual therapy to maintain glycaemic targets requires consideration of the impact of medication side-effects on comorbidities, as well as the burden of treatment and cost

The panel say that the lack of evidence over specific combinations of glucose-lowering therapies remains an issue, and more research is needed. The say: "As the cost implications for these various approaches is enormous, evidence is desperately needed. Different models of care are being implemented globally. Defining optimal cost-effective approaches to care, particularly in the management of patients —including those with multi-morbidity —is essential."

They add: "New questions arise from the recent cardiovascular outcomes studies. Do the cardiovascular and renal benefits of SGLT2 inhibitors and GLP-1 receptor agonists demonstrated in patients with established CVD extend to lower-risk patients? Is there additive benefit of use of GLP-1 receptor agonists and SGLT2 inhibitors for prevention of cardiovascular and renal events? If so, in what populations? Addressing these and other vital clinical questions will require additional investment in basic, translational, clinical and implementation research."

They conclude: "The management of hyperglycaemia in type 2 diabetes has become extraordinarily complex with the number of glucose-lowering medications now available. Patient-centred decision making and support and consistent efforts to improve diet and exercise remain the foundation of all glycaemic management. Initial use of metformin, followed by addition of glucose-lowering medications based on patient comorbidities and concerns is recommended as we await answers to the many questions that remain."

Explore further: Study: Improvement in glycemic parameters by adding dapagliflozin to metformin in T2D

Related Stories

Study: Improvement in glycemic parameters by adding dapagliflozin to metformin in T2D

October 1, 2018
Researchers used continuous glucose monitoring (CGM) to assess the effects of adding dapagliflozin to a regimen of either metformin or insulin in patients with type 2 diabetes (T2D) and found significant reductions in mean ...

No significant difference found between glucose-lowering drugs for risk of death

July 19, 2016
Among nearly 120,000 adults with type 2 diabetes, there were no significant differences in the associations between any of 9 available classes of glucose-lowering drugs (alone or in combination) and the risk of cardiovascular ...

Primary prevention could reduce heart disease among type 2 diabetes patients

August 7, 2017
In a Journal of the American College of Cardiology state of the art review published today, researchers from the division of cardiology and the Center for the Prevention of Cardiovascular Disease at the New York University ...

GLP-1 receptor agonists can manage postprandial glucose

November 17, 2015
(HealthDay)—Glucagon-like peptide 1 (GLP-1) receptor agonists appear beneficial for postprandial glucose management in type 2 diabetes, according to a report published in the October issue of Clinical Diabetes.

Researchers call for paradigm shift in type 2 diabetes treatment

June 20, 2017
Heart disease is a leading cause of death worldwide and exacerbated by type 2 diabetes, yet diabetes treatment regimens tend to focus primarily on blood sugar maintenance. This common approach to type 2 diabetes management ...

New oral diabetes drugs may also protect patients' kidney health

August 18, 2016
A recent study indicates that a new class of oral diabetes drugs may help protect patients' kidney health in addition to lowering their blood sugar levels. The findings appear in an upcoming issue of the Journal of the American ...

Recommended for you

Does diabetes damage brain health?

December 14, 2018
(HealthDay)—Diabetes has been tied to a number of complications such as kidney disease, but new research has found that older people with type 2 diabetes can also have more difficulties with thinking and memory.

Researchers study abnormal blood glucose levels of discharged patients

December 14, 2018
University of Minnesota Medical School researchers decided to delve into an area where little data currently exists. They wanted to know what happens after these patients with abnormal blood glucose measurements are discharged? ...

Researchers zero in on potential therapeutic target for diabetes, associated diseases

December 14, 2018
A recent study led by researchers in Texas A&M University's department of nutrition and food science shows how a novel regulatory mechanism serves as an important biomarker for the development of diabetes, as well as a potential ...

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Millions of low-risk people with diabetes may be testing their blood sugar too often

December 10, 2018
For people with Type 2 diabetes, the task of testing their blood sugar with a fingertip prick and a drop of blood on a special strip of paper becomes part of everyday life.

Very low calorie diets trialled by NHS to tackle diabetes

December 7, 2018
Hundreds of thousands of people will receive NHS help to battle obesity and type 2 diabetes under radical action set out by Simon Stevens, Chief Executive of NHS England.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.